In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas Pharma, Inc.

http://www.astellas.com

Latest From Astellas Pharma, Inc.

The Next Big Thing In Gene Therapy Might Not Be Gene Therapy

Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.

Gene Therapy Financing

Orphazyme Wants More Time To Deal With Late-Stage Issues For Arimoclomol In EU

Following Orphazyme’s disappointment in the US regarding its investigational drug for an ultrarare disease, the company has said it will need more time to address outstanding issues raised by EU reviewers about the same medicine.

Europe Drug Review

Boehringer & BridgeBio Seek EU Fast-Track Status; Enfortumab Vedotin Reverts To Standard Review

Applications for the accelerated assessment of planned EU marketing applications for two drugs are being considered by the European Medicines Agency.

Europe Review Pathway

Takeda Continues Recent Gene Therapy Partnering Spree With Poseida Pact

Takeda will use Poseida’s non-viral delivery and gene-editing capabilities for six liver- and hematopoietic stem cell-targeted gene therapies. The agreement follows recent gene therapy tie-ups with Selecta and Genevant.

Gene Therapy Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Advanced Cell Technology, Inc.
    • Agensys, Inc.
    • Audentes Therapeutics, Inc.
    • Fujisawa GmbH
    • Ganymed Pharmaceuticals AG GmbH
    • iota Biosciences
    • Mytogen, Inc.
    • Nanna Therapeutics Limited
    • Perseid Therapeutics LLC
    • Potenza Therapeutics Inc.
    • Ocata Therapeutics, Inc.
    • OSI Pharmaceuticals, LLC (Cell Pathways
    • Prosidion)
    • Yamanouchi Pharmaceutical Co., Ltd.
    • Ogeda S.A.
    • Mitobridge, Inc.
    • Mitokyne, Inc.
    • Quethera Limited
    • Universal Cells, Inc.
    • Xyphos Biosciences, Inc.
UsernamePublicRestriction

Register